Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Toxoplasmosis01:28

Toxoplasmosis

Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Diversity of Protists II01:27

Diversity of Protists II

Alveolates are a group of organisms recognized by the presence of alveoli, which are cytoplasmic sacs located beneath the cell membrane. While their function remains uncertain, alveoli may help regulate water balance by controlling how much water enters and leaves the cell. In dinoflagellates, these structures may serve as armor plates. There are three major types of alveolates: ciliates, which move using cilia; dinoflagellates, which use flagella for movement; and apicomplexans, which are...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Edible Plants with Antimicrobial Potential - Report of the Expert Meetings from Ibero-American Countries.

Planta medica·2026
Same author

Antileishmanial Activity of <i>Schinus terebinthifolia</i> Essential Oil: Chemistry, In Vitro and Mechanistic Studies.

Molecules (Basel, Switzerland)·2026
Same author

Sterol Endoperoxides and Their Antileishmanial Effects: Influence on Viability, Oxygen Metabolism and Sterol Synthesis.

Molecules (Basel, Switzerland)·2026
Same author

Protozoan Neglected Tropical Diseases (NTDs) Target Inhibition of Alkaloids from <i>Croton linearis</i> Jacq Leaves: A Molecular Docking and ADMET Approach.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

In vitro and in vivo activity of a lipid-based artemisinin formulation against Leishmania (Leishmania) amazonensis.

Experimental parasitology·2025
Same author

Cumulative Hepatoprotective, Antihyperlipidemic and Antioxidant Effects of Methanolic Seeds Extract of <i>Citrullus lanatus</i>, <i>Cucumis melo</i>, <i>Cucumis sativus</i>, and <i>Cucurbita maxima</i> With GC-MS Profile.

Food science & nutrition·2025

Related Experiment Video

Updated: Jun 1, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

Drug development to protozoan diseases.

Lianet Monzote1, Afshan Siddiq

  • 1Parasitology Department, Institute of Medicine Tropical "Pedro Kourí", Havana City, Cuba.

The Open Medicinal Chemistry Journal
|June 2, 2011
PubMed
Summary

Protozoan parasite diseases impact millions globally. New drug discovery is crucial as current treatments face challenges like resistance and poor safety, necessitating urgent development of novel anti-protozoan agents.

Area of Science:

  • Medicinal Chemistry
  • Parasitology
  • Drug Discovery

Background:

  • Protozoan parasite infections cause significant global mortality and morbidity, affecting over 500 million people.
  • Current disease control strategies are hampered by challenges in vector and reservoir management, and slow vaccine development.
  • Existing anti-protozoan chemotherapy, developed over 50 years ago, suffers from limitations including high cost, poor compliance, drug resistance, low efficacy, and adverse safety profiles.

Purpose of the Study:

  • To highlight recent advancements in the discovery of novel anti-protozoan drugs.
  • To address the urgent need for new therapeutic agents against protozoan parasitic diseases.
  • To provide an overview of developments in anti-protozoan drug discovery.

Main Methods:

Keywords:
Anti-infectiveanti-protozoandrugs.

Related Experiment Videos

Last Updated: Jun 1, 2026

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

  • Review of recent research and developments in anti-protozoan drug discovery.
  • Focus on novel therapeutic strategies and drug candidates.
  • Synthesis of information on the challenges and progress in the field.

    • Main Results:

    • Increased research efforts are being directed towards developing new drugs against protozoan parasites.
    • This special issue showcases significant advances in the identification and development of new anti-protozoan agents.
    • Emerging strategies aim to overcome the limitations of current therapies.

    Conclusions:

    • There is a critical need for novel anti-protozoan drugs due to the shortcomings of existing treatments.
    • Recent progress indicates a promising future for the development of effective therapies against protozoan parasitic diseases.
    • Continued research and development are essential for combating the global burden of these infections.